NCT06624644 2026-04-22A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaLinnaeus Therapeutics, Inc.Phase 2/3 Recruiting135 enrolled
NCT06581406 2026-04-02A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaReplimune, Inc.Phase 2/3 Recruiting280 enrolled